ECDC and EMCDDA technical guidance on prevention and control of infectious diseases among people who inject drugs
The content of this joint guidance was developed by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) with the support of a technical advisory group composed of policy makers, service providers, civil society representatives and preventative health experts from throughout the EU/EEA.
ECDC and EMCDDA technical guidance on prevention and control of infectious diseases among people who inject drugs - guidance in brief
This evidence-based guidance is designed to inform the development, monitoring and evaluation of national strategies and programmes in countries in Europe in order to reduce and prevent infections among people who inject drugs.
Rapid Risk Assessment: Potential public health risks related to communicable diseases at the WorldPride festival in Madrid, 23 June–2 July 2017
This rapid risk assessment reviews the health risks related to communicable diseases in the context of the WorldPride festival in Madrid, from 23 June to 2 July 2017.
EMCDDA and ECDC join forces to address the challenge of hepatitis
Hepatitis and other drug-related infectious diseases will be the focus of ‘Hepatitis week’, taking place at the EU drugs agency (EMCDDA) in Lisbon from 12–16 June 2017. The initiative will bring together some 100 specialists from: EU Member States, candidate and potential candidate countries to the EU, as well as partner agencies, civil society and professional organisations.
ECDC: around 9 million Europeans are affected by chronic hepatitis B or C
An estimated 4.7 million Europeans are living with chronic hepatitis B and almost 4 million (3.9) with chronic hepatitis C infection. However, large numbers of them are not even aware of their infection as they have not yet been tested and diagnosed.